Curaleaf Holdings (CURLF) Other Non-Current Liabilities (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Other Non-Current Liabilities of $1.2 million for Q4 2025, down 56.4% year-on-year from $2.8 million in Q4 2024, and down 56.4% on a QoQ basis from $2.8 million in Q4 2024.
Curaleaf Holdings (CURLF) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Other Non-Current Liabilities for 7 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 56.4% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 56.4% YoY) and the FY2025 annual result came in at $1.2 million, down 56.4% from the prior year.
- Other Non-Current Liabilities eased to $1.2 million in Q4 2025 per CURLF's latest filing, from $2.8 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for CURLF reached as high as $6.6 billion in Q1 2022 and fell as low as $298000.0 in Q3 2023.
- A 5-year average of $457.6 million and a median of $4.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 348055.95% — and 2023, when it slumped 96.99%.
- Year by year, Other Non-Current Liabilities stood at $38.0 million in 2021, then dropped by 23.38% to $29.1 million in 2022, then tumbled by 83.77% to $4.7 million in 2023, then slumped by 39.94% to $2.8 million in 2024, then plunged by 56.4% to $1.2 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.2 million, $2.8 million, and $3.7 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 298,000.00 |
| Jun 30, 2023 | 103.69 Mn |
| Dec 31, 2022 | 29.11 Mn |
| Sep 30, 2022 | 9.89 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 6.61 Bn |
| Dec 31, 2021 | 37.99 Mn |
| Sep 30, 2021 | 26.15 Mn |
| Jun 30, 2021 | 29.11 Mn |
| Mar 31, 2021 | 1.90 Mn |
| Dec 31, 2020 | 1.90 Mn |
| Sep 30, 2020 | 41.23 Mn |
| Dec 31, 2019 | 32.62 Mn |